132 related articles for article (PubMed ID: 35738590)
1. Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.
Albert DH; Goodwin NC; Davies AM; Rowe J; Feuer G; Boyiadzis M; Dorritie KA; Mancini M; Gandour-Edwards R; Jonas BA; Borthakur G; Aldoss I; Rizzieri DA; Odenike O; Prebet T; Singh S; Popovic R; Shen YU; McDaniel KF; Kati WM; Modi DA; Motwani M; Wolff JE; Frost DJ
In Vivo; 2022; 36(4):1615-1627. PubMed ID: 35738590
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Borthakur G; Odenike O; Aldoss I; Rizzieri DA; Prebet T; Chen C; Popovic R; Modi DA; Joshi RH; Wolff JE; Jonas BA
Cancer; 2021 Aug; 127(16):2943-2953. PubMed ID: 33934351
[TBL] [Abstract][Full Text] [Related]
3. Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia.
Zhang L; Cai T; Lin X; Huang X; Bui MH; Plotnik JP; Bellin RJ; Faivre EJ; Kuruvilla VM; Lam LT; Lu X; Zha Z; Feng W; Hessler P; Uziel T; Zhang Q; Cavazos A; Han L; Ferguson DC; Mehta G; Shanmugavelandy SS; Magoc TJ; Rowe J; Goodwin NC; Dorritie KA; Boyiadzis M; Albert DH; McDaniel KF; Kati WM; Konopleva M; Shen Y
Mol Cancer Ther; 2021 Oct; 20(10):1809-1819. PubMed ID: 34253595
[TBL] [Abstract][Full Text] [Related]
4. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.
Fiskus W; Cai T; DiNardo CD; Kornblau SM; Borthakur G; Kadia TM; Pemmaraju N; Bose P; Masarova L; Rajapakshe K; Perera D; Coarfa C; Mill CP; Saenz DT; Saenz DN; Sun B; Khoury JD; Shen Y; Konopleva M; Bhalla KN
Blood Cancer J; 2019 Jan; 9(2):4. PubMed ID: 30647404
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.
Bui MH; Lin X; Albert DH; Li L; Lam LT; Faivre EJ; Warder SE; Huang X; Wilcox D; Donawho CK; Sheppard GS; Wang L; Fidanze S; Pratt JK; Liu D; Hasvold L; Uziel T; Lu X; Kohlhapp F; Fang G; Elmore SW; Rosenberg SH; McDaniel KF; Kati WM; Shen Y
Cancer Res; 2017 Jun; 77(11):2976-2989. PubMed ID: 28416490
[TBL] [Abstract][Full Text] [Related]
6. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
Piha-Paul SA; Sachdev JC; Barve M; LoRusso P; Szmulewitz R; Patel SP; Lara PN; Chen X; Hu B; Freise KJ; Modi D; Sood A; Hutti JE; Wolff J; O'Neil BH
Clin Cancer Res; 2019 Nov; 25(21):6309-6319. PubMed ID: 31420359
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia.
Jiang W; Hou Q; Xu H; Yang K; Wang X; Zhang K; Zeng Y; Li W; Wang B; Luo G; Zhao X; Shen H; Xu Y; Wu X
J Med Chem; 2024 Jan; 67(2):1513-1532. PubMed ID: 38175809
[TBL] [Abstract][Full Text] [Related]
8. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
10. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors.
Lam LT; Lin X; Faivre EJ; Yang Z; Huang X; Wilcox DM; Bellin RJ; Jin S; Tahir SK; Mitten M; Magoc T; Bhathena A; Kati WM; Albert DH; Shen Y; Uziel T
Mol Cancer Ther; 2017 Aug; 16(8):1511-1520. PubMed ID: 28468776
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
[TBL] [Abstract][Full Text] [Related]
12. Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
McDaniel KF; Wang L; Soltwedel T; Fidanze SD; Hasvold LA; Liu D; Mantei RA; Pratt JK; Sheppard GS; Bui MH; Faivre EJ; Huang X; Li L; Lin X; Wang R; Warder SE; Wilcox D; Albert DH; Magoc TJ; Rajaraman G; Park CH; Hutchins CW; Shen JJ; Edalji RP; Sun CC; Martin R; Gao W; Wong S; Fang G; Elmore SW; Shen Y; Kati WM
J Med Chem; 2017 Oct; 60(20):8369-8384. PubMed ID: 28949521
[TBL] [Abstract][Full Text] [Related]
13. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
[TBL] [Abstract][Full Text] [Related]
14. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
15. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
Faivre EJ; Wilcox D; Lin X; Hessler P; Torrent M; He W; Uziel T; Albert DH; McDaniel K; Kati W; Shen Y
Mol Cancer Res; 2017 Jan; 15(1):35-44. PubMed ID: 27707886
[TBL] [Abstract][Full Text] [Related]
16. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
[TBL] [Abstract][Full Text] [Related]
17. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
18. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
[TBL] [Abstract][Full Text] [Related]
19. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
20. An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia.
Her Z; Yong KSM; Paramasivam K; Tan WWS; Chan XY; Tan SY; Liu M; Fan Y; Linn YC; Hui KM; Surana U; Chen Q
J Hematol Oncol; 2017 Oct; 10(1):162. PubMed ID: 28985760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
